Literature DB >> 20117886

[Demons and Meigs syndromes and pseudosyndromes today].

G-H Brun1.   

Abstract

There is a total confusion between Demons or Meigs syndromes and pseudosyndromes.The need for greater precision in publications titles has become an emergency. We have analysed 297 observations gathered in litterature from 1904 to 2004. The increase in the number of Meigs pseudosyndromes based on diverse associated condition means that we must include under the name Demons syndrome, as he did himself, all tumours of the female genital tract, providing they are benign, wherever the effusion takes place, reserve the name Demons Meigs because it has been used historically and because it was Meigs wish, solely for fibrothecomas of the ovary and for tumours of the granulosa bring together under the name Demons pseudosyndrome all other non tumoral benign entities. Malignant tumours, with or without malignant cells in the effusions are not pseudosyndromes but authentic neoplastic lesions. An over-lax definition of pseudosyndromes runs the risk of the name simply becoming a catch-all term. On the other hand we can say that 100years later diagnosis is not earlier, a bilateral tumor is not a rarity, mechanisms of effusions genesis remain mysterious and the treatment has been enriched with coeliosurgery. Copyright 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20117886     DOI: 10.1016/j.jgyn.2009.12.003

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  2 in total

1.  [Pseudo-Meigs syndrome: report of a case].

Authors:  Benjelloun Hanane; Morad Sanaa; Zaghba Nahid; Bakhatar Abdelaziz; Yassine Najiba; Bahlaoui Abdelkrim
Journal:  Pan Afr Med J       Date:  2014-03-10

Review 2.  Pleural Effusion in Meigs' Syndrome-Transudate or Exudate?: Systematic Review of the Literature.

Authors:  Rafal Krenke; Marta Maskey-Warzechowska; Piotr Korczynski; Monika Zielinska-Krawczyk; Joanna Klimiuk; Ryszarda Chazan; Richard W Light
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.